While Brivaracetam is being evaluated as an adjunctive therapy in patients diagnosed with Epilepsy and partial onset seizures, animal models have piqued the curiosity of R&D experts as to Brivaracetam being a potential treatment for Alzheimer’s patients. As a unique product with a high-affinity synaptic vesicle protein 2A ligand, Brivaracetam is currently marketed by UCB, which announced both US and EU regulatory filings in January 2015. Ongoing study remains a standard for this investigational antiepileptic drug, with new information being shared regarding this novel and effectual product in a timely fashion.
Recent studies emerged on mice who possessed various strains of transgenic Alzheimer’s disease and who were given the antiepileptic drugs Ethosuximide and Brivaracetam. The idea was that these drug therapies would suppress epileptiform activity and reverse memory impairments and synapse loss in the mice. Results were intriguing, with two transgenic mouse models of Alzheimer’s disease showed a presence of spike-wave discharges which correlated with impairments in their spatial memory. While both Ethosuximide and Brivaracetam were shown to reduce spike-wave discharges, only Brivaracetam reversed the memory impairments in the mice. Further study is in order to determine if Brivaracetam can treat humans with Alzheimer’s disease.
The importance of Brivaracetam to treat epilepsy is paramount, and study investigators are anxiously awaiting FDA and EU approval. As one of the most common neurological issues epilepsy is believed to affect roughly 1% of the population worldwide. Only one-third of patients achieve seizure control from current drug therapies approved today, leaving a great need for new and efficacious treatments. As a Levetiracetam derivative Brivaracetam is a second generation therapy which has proven successfully in studies to target the synaptic vesicle protein 2A. Brivaracetam has also shown in trials to have efficacy for the treatment of progressive myoclonus epilepsy, and it is also in development to become a potential add-on treatment for focal epilepsy. Brivaracetam has demonstrated tolerability in many studies of patients with epilepsy. Three phase 3 studies, which involved more than 3,000 adults and children have been conducted, with one specific phase 3 study being deemed extremely successful. This study included 398 adult patients with epilepsy in a placebo controlled and double blind trial. The adults who were administered 100 milligrams daily of Brivaracetam experienced a reduced rate of baseline-adjusted focal seizures by 11.7% over the patients who were dosed with the placebo. Additionally, 36% of the patients who received Brivaracetam had a seizure reduction of 50% or greater as compared to the placebo patient population. The future looks bright for Brivaracetam.
LGM Pharma can assist clients as a supplier/distributor of the API Brivaracetam CAS# 357336-20-0 for research and development purposes. Clients can be assured of quality API products and continuous support throughout the R&D process.
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e) +A13(1). Any patent infringement and resulting liability is solely at buyer risk.